Professor Jacob Sherkow was quoted in a STAT News story on the Cassava Sciences treatment for Alzheimer's disease that has recently come under fire. The company's CEO (Remi Barbier) has been on the defensive since a citizen petition filed with the FDA asked the agency to halt clinical trials and investigate alleged data manipulation.
Sherkow, via tweet, said, “I don’t think the complaint is a fear that the drug isn’t ultimately *efficacious.* It’s that the IND was seemingly obtained from fraudulent data.”
Read the full story.